More than 70% of drug candidates worldwide are chiral. Typically, for chiral API, only one enantiomer or diasteromer is biologically active or desirable. Therefore, the production of enantiopure compounds or diastereomers is imperative. To produce small molecule drugs with desired chirality, chiral separation via crystallization can be much more economical and environmentally favorable than chromatography.
• Classical Chiral Resolution
Classical chiral resolution of an enantiomeric acid or base via diastereomeric salt formation and crystallization is a
common approach to separate the desired enantiomer from its racemic mixture. From screening for desired resolving
agent, polymorph and solvent to design and optimization of crystallization process, we offer solutions catering various
specific needs in chiral separation.
• Preferential Crystallization
The upper limit of 50% yield to an enantiopure compound by conventional chiral separation methods can be surpassed
by combining racemization with crystallization of an enantiomer from its racemic mixture (or conglomerate). Identification
of proper racemizing agent and implementation of crystallization engineering effectively aid our successful design and
optimization of preferential crystallization processes.Production of Metastable Form.